Research graph
References from Momelotinib induces hemoglobin improvement and symptom control in PCM1::JAK2-associated myeloid neoplasm. Local targets link to admitted publications; unresolved targets remain external evidence.
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
10.1182/blood.2022015850 · 2022 · External reference
The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms
10.1038/s41375-022-01613-1 · 2022 · External reference
PCM1-JAK2 fusion tyrosine kinase gene-related neoplasia: a systematic review of the clinical literature
10.1093/oncolo/oyac072 · 2022 · External reference
Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study
10.1038/s41379-018-0165-9 · 2019 · External reference
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes
10.1002/ajh.25825 · 2020 · External reference
SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-Naïve patients with myelofibrosis
10.1200/jco.2017.73.4418 · 2017 · External reference
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
10.1016/s0140-6736(22)02036-0 · 2023 · External reference
MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis
10.1200/jco.2018.78.9867 · 2018 · External reference
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
10.1056/nejmoa1110557 · 2012 · External reference
Clinical significance of emergent leukocytosis in patients with myelofibrosis receiving JAK inhibitor therapy
10.1182/blood-2020-139936 · 2020 · External reference
Diagnosis and treatment of myeloproliferative neoplasms with PCM1-JAK2 rearrangement: case report and literature review
10.3389/fonc.2021.753842 · 2021 · External reference
Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes
10.1007/s00277-014-2221-y · 2015 · External reference
Myeloid/lymphoid neoplasms with eosinophilia and TK fusion genes, version 3.2021, NCCN clinical practice guidelines in oncology
10.6004/jnccn.2020.0042 · 2020 · External reference
Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT
10.1182/blood.2024028000 · 2025 · External reference
Comparison of outcomes of allogeneic transplantation for primary myelofibrosis among hematopoietic stem cell source groups
10.1016/j.bbmt.2019.02.019 · 2019 · External reference
